Washington (GNP): NIH Mitragynine Opioid Treatment 2026 research has reached a landmark milestone, as the National Institutes of Health announced that its Investigational New Drug application for mitragynine — the primary psychoactive compound found in the kratom plant — has taken effect with the United States Food and Drug Administration. The development paves the way for the first-ever human clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder, offering new hope to millions of Americans struggling with addiction.
NIH Mitragynine Opioid Treatment 2026 research cleared a critical regulatory hurdle as the Investigational New Drug application submitted to the FDA officially took effect, authorising NIH investigators to proceed with a Phase I clinical trial. Researchers at NIH and the University of Florida developed the purified formulation of mitragynine to be used in the trial, as well as conducting the extensive preclinical work that led to the submission of the IND application.
Nora Volkow, Director of NIH’s National Institute on Drug Abuse, described the development as a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder, which has contributed to historically high overdose mortality rates across the United States.
What is Mitragynine and Why Does It Matter
Mitragynine is the primary psychoactive compound found in Mitragyna speciosa, commonly known as kratom, a tropical tree native to Southeast Asia. Interest in kratom as a potential treatment for opioid use disorder has grown significantly in recent years, with many individuals reportedly using it to manage opioid withdrawal, pain, and other conditions.
While the kratom plant contains many compounds known to interact with opioid receptors, research indicates that its potential therapeutic effects are likely driven by the slow conversion of mitragynine within the body. Preclinical studies led by scientists at the University of Florida, NIH’s National Center for Advancing Translational Sciences, and the National Institute on Drug Abuse demonstrated that mitragynine administration, across several doses, did not raise significant safety concerns in animal models. However, the compound in isolation had not previously been studied in humans, until now.
Also Read: Kamal Calls for Coordinated Action to Control HIV
First Human Safety Study Now Authorized
With the IND now in effect, NIH scientists are planning to conduct the first randomised, double-blind, placebo-controlled study in history to assess the safety and tolerability of the mitragynine formulation in human participants. This rigorous study design represents the gold standard in clinical research and will provide the scientific community with reliable, high-quality data on how mitragynine behaves in the human body.
Joni Rutter, Director of NIH’s National Center for Advancing Translational Sciences, expressed cautious optimism about the path ahead, noting that years of promising laboratory research had finally created the conditions necessary to examine mitragynine’s potential in people. She expressed hope that the work would ultimately lead to a new treatment option for individuals with opioid use disorder and help support a clear path to recovery.
The NIH Mitragynine Opioid Treatment 2026 trial forms part of the Helping to End Addiction Long-term Initiative, more commonly known as the NIH HEAL Initiative. This broad, trans-agency effort was launched by NIH to speed scientific solutions to stem the national opioid public health crisis. The HEAL Initiative supports research across the full spectrum of addiction and pain management, from prevention and treatment to recovery support and overdose reversal.
The opioid crisis has claimed hundreds of thousands of American lives over the past two decades and continues to exact a devastating toll on individuals, families, and communities across the country. The development of new, effective treatment options remains one of the most urgent priorities in American public health.
The opioid use disorder crisis in the United States has reached catastrophic proportions, with overdose deaths remaining at historically high levels despite significant investment in prevention and treatment programmes. Current approved treatments for opioid use disorder, including methadone, buprenorphine, and naltrexone, have proven effective for many patients but do not work for everyone.
The search for new treatment options is therefore critical, and the NIH Mitragynine Opioid Treatment 2026 trial represents a significant and potentially transformative step in that ongoing effort.
